文献速递消化道肿瘤与早癌消化内镜

基于粪便microRNA的算法提高粪便免疫化学检测结直肠癌筛查效果

Fecal MicroRNA-Based Algorithm Increases Effectiveness of Fecal Immunochemical Test-Based Screening for Colorectal Cancer.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-02-28

该研究基于767例粪便免疫化学检测(FIT)阳性后接受结肠镜检查者的数据,评估结合粪便2种microRNA、粪便血红蛋白浓度及年龄性别的miRFec算法。结果显示miRFec评分与进展期结直肠肿瘤独立相关(P < .001),鉴别结直肠癌与非进展期腺瘤或正常结肠镜的AUC为90%(95% CI, 86-94),高危组发生进展期结直肠肿瘤的可能性是低危组的8倍;在50%特异度截断值下,miRFec算法可识别97%的结直肠癌患者,并使264例(34.4%)受检者避免结肠镜检查。

要点

  • miRFec评分与进展期结直肠肿瘤独立相关(P < .001)。
  • 鉴别结直肠癌与非进展期腺瘤或正常结肠镜的AUC为90%。
  • 50%特异度下可识别97%结直肠癌,34.4%受检者避免结肠镜。

核心结论

  • 基于粪便2种microRNA、粪便血红蛋白、年龄和性别的miRFec算法可区分结直肠癌与非进展期腺瘤或正常结肠镜,AUC为90%,并避免34%的结肠镜检查。

研究设计与样本

  • 研究纳入2011年3月至2017年5月西班牙巴塞罗那基于人群结直肠癌筛查项目中767例FIT阳性后接受结肠镜检查者的数据和粪便样本。
  • 从原始FIT采集装置缓冲液中分离粪便miRNA,采用定量逆转录PCR分析。

主要发现

  • 767例受试者中,414例(54.0%)结肠镜检出进展期结直肠肿瘤(67例结直肠癌和347例进展期腺瘤),353例(46.0%)为非进展期腺瘤(n=136)或正常检查(n=217)。
  • miRFec算法评分(1-4)与进展期结直肠肿瘤存在独立关联(P < .001)。
  • miRFec算法鉴别结直肠癌与非进展期腺瘤或正常结肠镜的受试者工作特征曲线下面积为90%(95% CI, 86-94)。
  • miRFec评分第4四分位(高于3.09,高危组)受试者发生进展期结直肠肿瘤的可能性是第1四分位(低于2.14,低危组)的8倍。
  • 低危组检测进展期结直肠肿瘤的阳性预测值低于30%。

关键数值与推荐

  • 采用50%特异度截断值时,miRFec算法识别97%的结直肠癌患者,并使264例(34.4%)受试者避免结肠镜检查。

临床怎么用

  • 在FIT阳性人群中,miRFec算法可用于优先安排进展期结直肠肿瘤高风险者接受结肠镜检查。
  • miRFec算法可识别低风险个体,从而避免不必要的结肠镜检查。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: An algorithm based on fecal levels of 2 microRNAs (miR-421 and miR-27a-3p), fecal hemoglobin concentration, and patient age and sex can identify patients with advanced colorectal neoplasia. We investigated whether this algorithm, called miRFec, could increase effectiveness and efficiency of fecal immunochemical test (FIT)-based colorectal cancer (CRC) screening programs. METHODS: We obtained data and fecal samples from 767 persons with a positive result from the FIT who then underwent colonoscopy examination while participating a population-based CRC screening program, from March 2011 through May 2017 in Barcelona, Spain. Fecal miRNAs were isolated from the buffer contained in the original FIT collection device and analyzed by quantitative reverse transcription PCR. Aims were to evaluate the usefulness of the miRFec algorithm in identifying persons at greatest risk for CRC who should be prioritized for colonoscopy examination and individuals at low risk for whom colonoscopy could be avoided. RESULTS: Of the 767 study subjects, 414 (54.0%) were found by colonoscopy to have advanced colorectal neoplasia (67 with CRC and 347 with advanced adenomas) and 353 (46.0%) were found to have either non-advanced adenomas (n = 136) or a normal examination (n = 217). MiRFec algorithm scores (1-4) were independently associated with the presence of advanced colorectal neoplasia (P < .001). The miRFec algorithm differentiated patients with CRC from those with non-advanced adenomas or normal colonoscopy with an area under the receiver operating characteristic curve of 90% (95% CI, 86-94). Subjects with miRFec scores in the 4th quartile (above 3.09, high-risk group) were 8-fold more likely to have advanced colorectal neoplasia than subjects with miRFec scores in the 1st quartile (below 2.14, low-risk group). Subjects in the low-risk group had a positive predictive value below 30% for detection of advanced colorectal neoplasia. When we used a 50% specificity cut-off value, the miRFec algorithm identified 97% of patients with CRC and would allow 264 subjects (34.4%) to avoid colonoscopy examination. CONCLUSIONS: An algorithm based on fecal levels of 2 miRNAs and hemoglobin, patient age and sex (miRFec) differentiated patients with CRC from those with non-advanced adenomas or normal colonoscopy with an area under the receiver operating characteristic curve value of 90% and avoided 34% of colonoscopies. Inclusion of this algorithm in FIT-based CRC screening programs could increase their effectiveness and efficiency.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Duran-Sanchon S, Moreno L, Gómez-Matas J, et al. Fecal MicroRNA-Based Algorithm Increases Effectiveness of Fecal Immunochemical Test-Based Screening for Colorectal Cancer. Clin Gastroenterol Hepatol. 2020. PMID: 32113893. doi:10.1016/j.cgh.2020.02.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。